Trial · NCT03108352
Conbercept Ophthalmic Injection for Patients With Macular Edema Caused by Branch Retinal Vein Occlusion
NCT03108352, Phase 3, Completed, Chengdu Kanghong Biotech Co., Ltd.
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. Conbercept Ophthalmic Injection for Patients With Macular Edema Caused by Branch Retinal Vein Occlusion. Trials, record NCT03108352. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03108352
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Conbercept Ophthalmic Injection for Patients With Macular Edema Caused by Branch Retinal Vein Occlusion
- NCT number
- NCT03108352
- Status
- Completed
- Phases
- Phase 3
- Enrollment
- 255 participants, actual
- Lead sponsor
- Chengdu Kanghong Biotech Co., Ltd.
- Conditions
- Branch Retinal Vein Occlusion, Macular Edema
- Interventions
- Conbercept ophthalmic injection, sham/Conbercept ophthalmic injection
- First posted
- 2017-04-11
- Last updated
- 2022-07-15
Source ClinicalTrials.gov
Registered outcomes13
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Best Corrected Visual Acuity | month 6 | Compare mean changes in Best Corrected Visual Acuity (BCVA) from baseline between the Conbercept ophthalmic injection treatment group (treatment group) and the control group at month 6. |
| Secondary | Best Corrected Visual Acuity (BCVA) | month 3 and month 12 | 1\>o evaluate mean changes in BCVA from baseline of the treatment group and the control group at month 3 and 12. |
| Secondary | Central Retinal Thickness | month 3, month 6 and month 12 | To evaluate mean changes in Central Retinal Thickness (CRT) from baseline of the treatment group and the control group at month 3, 6 and 12. |
| Secondary | resue treament | month 6 and month 12 | To evaluate the number of subjects who received laser rescue treatment of the treatment group and the control group at month 6 and 12. |
| Secondary | Number of participants with treatment-related the systemic and ocular safely as assessed | up to 12.5 months | To evaluate the systemic and ocular safety of the treatment group and the control group. |
| Secondary | distribution of BCVA changes | month 3, month 6 and month 12 | To evaluate the distribution of BCVA changes from baseline of the treatment group and the control group at month 3, 6 and 12. |
| Secondary | mean changes in BCVA | month 0,month 1,month 2,month 3,month 4,month 5,month 6,month 7,month 8,month 9,month 10,month 11 and month 12 | To evaluate mean changes in BCVA from baseline of the treatment group and the control group at every visit. |
| Secondary | Change in image | month 0,month 1,month 2,month 3,month 4,month 5,month 6,month 7,month 8,month 9,month 10,month 11 and month 12 | To evaluate the average changes in imaging findings (e.g., CRT and total macular volume) relative to the baseline for treatment group and control group at each follow-up visit. |
| Other | Immunogenic positive response in the treatment group | baseline,month 6, month 12 | Number of participants with Treatment-Ralated positive response to anti-drug antibody（ADA）or neutralizing antibody(Nab) in the treatment group at baseline,6 and 12months. |
| Other | Immunogenic positive response in the control group | baseline,month 6, month 12 | Number of participants with Treatment-Ralated positive response to anti-drug antibody（ADA）or neutralizing antibody(Nab) in thecontrol group at baseline,6 and 12months. |
1 to 10 of 13Source ClinicalTrials.gov
See all 13 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers2
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03108352
GET https://conductscience.org/api/trials/v1/NCT03108352/registered